PET Radioactive Tracers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PET Radioactive Tracers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global PET radioactive tracers market has witnessed remarkable expansion reaching a market value of US$ 999 million in 2024, according to a recent study by Fairfield Market Research. The market is projected to maintain its upward trajectory, potentially reaching a valuation of US$ 1700 million by the end of 2031.

Radiopharmaceuticals Revolutionize Medical Imaging

Radiopharmaceuticals, also known as radioactive tracers or radiotracers, play a crucial role in medical imaging by assisting in locating diseased areas before further treatment procedures. These tracers contain a small amount of a radioactive substance emitting radiation, which specialized imaging equipment like single-photon emission computed tomography (SPECT) and positron emission tomography (PET) scanners can detect.

Recent years have witnessed regulatory approvals for various radiopharmaceuticals by esteemed authorities such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). These groundbreaking products cater to a wide range of applications, including cancer imaging and therapy, neurological disorders, and cardiology.

Gallium-68 Takes Center Stage

Gallium-68 (68Ga) has emerged as a significant player in nuclear medicine, particularly in the diagnosis and assessment of prostate cancer. The development relies heavily on the integration of technological advancements and the introduction of a groundbreaking radiotracer, 68Ga-PSMA-11, pioneered by the University of Heidelberg. The market authorization of the first 68Ge/68Ga generator by German manufacturer Eckert & Ziegler has further facilitated the penetration of the 68Ga-PSMA-11 tracer for prostate cancer treatment.

Factors Driving Demand for PET Radioactive Tracers
• Increasing Global Cancer Prevalence: Cancer, a complex disease requiring accurate diagnosis and effective treatment, has led to the growing demand for advanced imaging techniques like SPECT and PET, which rely on radiopharmaceuticals. The rising incidence of cancer worldwide is a significant driver for the PET radioactive tracers market.
• Supply Chain Challenges: The reliance on imported radiopharmaceuticals in many countries can result in supply chain problems, delays, and increased costs. To overcome this, radiopharmaceutical manufacturers are focusing on domestic radioisotope production, ensuring a stable supply of products.
• Investments in Domestic Production Facilities: Governments and private companies are investing in building domestic radiopharmaceutical production facilities. These initiatives not only ensure a stable supply but also create jobs, improve healthcare access, and enhance healthcare outcomes.

Challenges to Adoption
• Limited Imaging Time: Radiopharmaceuticals have shorter half-lives, limiting imaging time. For certain imaging protocols requiring longer durations, such as some dynamic PET studies, this can pose challenges.
• Availability in Clinical Settings: Radiopharmaceuticals with shorter half-lives may not be available in all clinical settings, limiting their use in some scenarios.

Country-wise Insights

United States: The U.S. dominates the North American PET radioactive tracers market, driven by the increasing utilization of PET scanning in oncology and neurology.

China: Significant investments in cyclotron facilities and radioactive tracer production capabilities have positioned China as a prominent market player, producing isotopes for medical imaging applications.

Germany: The burden of neurological disorders, including Alzheimer's and Parkinson's disease, in Germany has led to the growing use of PET-CT imaging in their diagnosis and management.

Competitive Landscape

The PET radioactive tracers market is characterized by a consolidated landscape with a few key players. Companies are actively expanding their presence in emerging markets, exploring strategic partnerships, acquisitions, and mergers to drive growth.

Key Companies in the Market:
• Eli Lilly and Company
• Blue Earth Diagnostics
• Lantheus
• Siemens Healthcare Private Limited
• GE Healthcare
• And more.

Key Segments of PET Radioactive Tracers Industry Research

Product:
• F-18
Florbetapir
Florbetaben
Flutemetamol
Fludeoxyglucose
Sodium Fluoride
Others
• C-11
Choline
Methionine
Others
• Ga-68
DOTA-TOC
DOTATATE
DOTANOC
Others
• O-15
• N-13
• Cu-64

Application:
• Neurological Disorders
Alzheimer’s Disease
Dementia
Others
• Cancer Diagnosis & Prognosis
Solid Tumors
Hematology Tumors
• Cardiac Dysfunctions
Myocardial Infarction
Others
• Infectious Disease Diagnosis
• Others

End User:
• Hospitals
• Speciality Diagnostic Centers
• Cancer Research Centers
• Academic & Research Institutes

Region:
• North America
• Latin America
• East Asia
• South Asia & Pacific
• Western Europe
• Eastern Europe
• Central Asia
• Russia & Belarus
• Balkan & Baltic Countries
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.